An International Multicenter Randomized Double-blind Placebo-controlled Clinical Study of the Efficacy and Safety of Subcutaneous BCD-085 in Patients With Psoriatic Arthritis
Latest Information Update: 16 Jul 2025
At a glance
- Drugs Netakimab (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms PATERA
- Sponsors Biocad
Most Recent Events
- 08 Jul 2025 Status changed from active, no longer recruiting to completed.
- 05 Jun 2021 Results of subanalysis; assessing ACR (American College of Rheumatology) 20/50/70 response rate in PsA patients with/without the axial disease, presented at the 22nd Annual Congress of the European League Against Rheumatism
- 05 Jun 2021 Results of subanalysis assessing effect of Netakimab on domains of EQ-5D-5L in patients with inflammatory back pain and without at baseline presented at the 22nd Annual Congress of the European League Against Rheumatism